Asciminib is a potent inhibitor of ABL/BCR::ABL1 tyrosine kinase. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by specifically targeting the ABL myristoyl pocket.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Asciminib is the active ingredient of these drugs:
Australia Canada France Lithuania United Kingdom
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):